Understanding presentation of viral antigens to CD8+ T cells in vivo: The key to rational vaccine design

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 651-682

  Yewdell, Jonathan W ^a   Haeryfar, S M Mansour ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antigen presentation; CTL; MHC; Virus

Indexed keywords

CD8 ANTIGEN; MEMBRANE PROTEIN; VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; CROSS PRESENTATION; DRUG DESIGN; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MICE; VIRAL VACCINES; VIRUS DISEASES;

EID: 17644393143     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115702     Document Type: Review

References (105)

1. Metchnikoff É. 1902. Immunität bei Infektionskrankheiten. Jena, Germany: Fischer
2. Jerne NK. 1985. The generative grammar of the immune system. Science 229:1057-59
3. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-11
4. Davis MM, Krogsgaard M, Huppa JB, Sumen C, Purbhoo MA, et al. 2003. Dynamics of cell surface molecules during T cell recognition. Annu. Rev. Biochem. 72:717-42
5. Yewdell JW, Hill AB. 2002. Viral interference with antigen presentation. Nat. Immunol. 3:1019-25
6. Day PM, Esquivel F, Lukszo J, Bennink JR, Yewdell JW. 1995. Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. Immunity 2:137-47
7. Song R, Harding CV. 1996. Roles of proteosomes, transporter for antigen presentation (TAP), and b2-microglobulin in the processing of bacterial or participate antigens via an alternate class I MHC processing pathway. J. Immunol. 156:4182-90
8. + T-cell response. Nat. Rev. Immunol. 4:595-602
9. + T cell responses. J. Immunol. 167:3577-84
10. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, et al. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-64
11. Debrick JE, Campbell PA, Staerz UD. 1991. Macrophages as accessory cells for class I MHC-restricted immune responses. J. Immunol. 147:2846-51
12. + T cells. J. Immunol. 158:1749-55
13. Sigal LJ, Crotty S, Andino R, Rock KL. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398:77-80
14. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, et al. 2002. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3:1135-41
15. Bacik I, Cox JH, Anderson R, Yewdell JW, Bennink JR. 1994. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J. Immunol. 152:381-87
16. Lenz LL, Butz EA, Bevan MJ. 2000. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med. 192:1135-42
17. Sigal LJ, Rock KL. 2000. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 192:1143-50
18. + T cells by exogenous cell-associated antigens. Immunity. 17:211-20
19. Shortman K, Liu YJ. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151-61
20. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, et al. 2004. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199:9-26
21. + dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-12. J. Immunol. 170:4437-40
22. + dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172:1996-2000
23. + dendritic cells but not by Langerhans cells. Science 301:1925-28
24. Belz GT, Smith CM, Kleinen L, Reading P, Brooks A, et al. 2004. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc. Natl. Acad. Sci. USA 101:8670-75
25. + T cells during pulmonary influenza virus infection. J. Immunol. 173:1209-18
26. Mintern J, Li M, Davey GM, Blanas E, Kurts C, et al. 1999. The use of carboxyfluorescein diacetate succinimidyl ester to determine the site, duration and cell type responsible for antigen presentation in vivo. Immunol. Cell Biol. 77:539-43
27. Legge KL, Braciale TJ. 2003. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 18:265-77
28. Mempel TR, Scimone ML, Mora JR, Von Andrian UH. 2004. In vivo imaging of leukocyte trafficking in blood vessels and tissues. Curr. Opin. Immunol. 16:406-17
29. Cahalan MD, Parker I, Wei SH, Miller MJ. 2003. Real-time imaging of lymphocytes in vivo. Curr. Opin. Immunol. 15:372-77
30. + T cells by infected dendritic cells in vivo. Nat. Immunol. 3:265-71
31. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. 2000. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J. Exp. Med. 192:1425-40
32. + T cell cross-priming via transfer of proteasome substrates. Science 304:1318-21
33. Doherty PC, Christensen JP. 2000. Accessing complexity: the dynamics of virus-specific T cell responses. Annu. Rev. Immunol. 18:561-92
34. + T cells. J. Virol. 77:2445-51
35. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG. 2002. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol. 168:834-38
36. Mempel TR, Henrickson SE, Von Andrian UH. 2004. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427:154-59
37. Yewdell JW, Bennink JR, Hosaka Y. 1988. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239:637-40
38. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:2795-804
39. Bevan MJ. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283-88
40. + T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1-77
41. Hudrisier D, Bongrand P. 2002. Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J. 16:477-86
42. + dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J. Exp. Med. 189:593-98
43. Bachmann MF, Kundig TM, Freer G, Li Y, Kang CY, et al. 1994. Induction of protective cytotoxic T cells with viral proteins. Eur. J. Immunol. 24:2228-36
44. Bachmann MF, Oxenius A, Pircher H, Hengartner H, Ashton-Richardt PA, et al. 1995. TAP 1-independent loading of class I molecules by exogenous viral proteins. Eur. J. Immunol 25:1739-43
45. Zinkernagel RM. 2002. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32:2385-92
46. + T cells by viral and tumor antigens is a robust phenomenon. Eur. J. Immunol. 34:194-99
47. + T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J. Immunol. 173:5021-27
48. Freigang S, Egger D, Bienz K, Hengartner H, Zinkernagel RM. 2003. Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming. Proc. Natl. Acad. Sci. USA 100:13477-82
49. Prasad SA, Norbury CC, Chen W, Bennink JR, Yewdell JW. 2001. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J. Immunol. 166:4809-12
50. Bennink JR, Yewdell JW. 1990. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Top. Microbiol. Immunol. 163:153-84
51. Coupar BEH, Andrew ME, Both GW, Boyle DB. 1986. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 16:1479-87
52. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, et al. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA 94:3183-88
53. + T cells in vivo. J. Immunol. 166:4355-62
54. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. 2003. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Sci. USA 100:12889-94
55. + T cells. J. Immunol. 168:5403-8
56. + CTL following exposure to vaccinia virus via different route? J. Immunol. 169:4222-29
57. Shen L, Sigal LJ, Boes M, Rock KL. 2004. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21:155-65
58. Gold MC, Munks MW, Wagner M, Koszinowski UH, Hill AB, Fling SP. 2002. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J. Immunol. 169:359-65
59. Holtappels R, Podlech J, Pahl-Seibert MF, Julch M, Thomas D, et al. 2004. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J. Exp. Med. 199:131-36
60. Hengel H, Reusch U, Geginat G, Holtappels R, Ruppert T, et al. 2000. Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J. Virol. 74:7861-68
61. Dantuma NP, Sharipo A, Masucci MG. 2002. Avoiding proteasomal processing: the case of EBNA1. Curr. Top. Microbiol. Immunol. 269:23-36
62. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791-802
63. Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, et al. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199:1409-20
64. Yin Y, Manoury B, Fahraeus R. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301:1371-74
65. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199:1421-31
66. Jones RJ, Smith LJ, Dawson CW, Haigh T, Blake NW, Young LS. 2003. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing. Virology 313:663-76
67. + T lymphocytes. J. Exp. Med. 199:459-70
68. Lizée G, Basha G, Tiong J, Julien JP, Tian M, et al. 2003. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat. Immunol. 4:1065-73
69. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6:715-26
70. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-15
71. Srivastava P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20:395-425
72. Shen L, Rock KL. 2004. Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 101:3035-40
73. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. 2004. Antigen bias in T cell cross-priming. Science 304:1314-17
74. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, et al. 2003. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18:343-54
75. Serna A, Ramirez MC, Soukhanova A, Sigal LJ. 2003. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells. J. Immunol. 171:5668-72
76. +-T- lymphocyte immunodominance hierarchy than infectious virus. J. Virol. 77:4679-84
77. Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV. 2002. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J. Exp. Med. 196:1447-59
78. Baker-LePain JC, Reed RC, Nicchitta CV. 2003. ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. Curr. Opin. Immunol. 15:89-94
79. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. 2002. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23:130-35
80. Reed RC, Berwin B, Baker JP, Nicchitta CV. 2003. GRP94/gp96 elicits ERK activation in murine macrophages: a role for endotoxin contamination in NF-κB activation and nitric oxide production. J. Biol. Chem. 278:31853-60
81. Falk K, Rötzschke O, Rammensee H-G. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-51
82. Anton LC, Yewdell JW, Bennink JR. 1997. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J. Immunol. 158:2535-42
83. Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, et al. 2003. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18:97-108
84. Fruci D, Lauvau G, Saveanu L, Amicosante M, Butler RH, et al. 2003. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J. Immunol. 170:2977-84
85. Kunisawa J, Shastri N. 2003. The group II chaperonin TRiC protects proteolytic intermediates from degradation in the MHC class I antigen processing pathway. Mol. Cell 12:565-76
86. MacAry PA, Javid B, Floto RA, Smith KG, Oehlmann W, et al. 2004. HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity 20:95-106
87. Storni T, Bachmann MF. 2004. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J. Immunol. 172:6129-35
88. Fonteneau JF, Larsson M, Bhardwaj N. 2002. Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr. Opin. Immunol. 14:471-77
89. Albert ML. 2004. Death-defying immunity: Do apoptotic cells influence antigen processing and presentation? Nat. Rev. Immunol 4:223-31
90. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. 2003. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J. Immunol. 170:2302-9
91. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. 2001. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J. Immunol. 166:3717-23
92. Wilson NS, Villadangos JA. 2004. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv. Immunol. In press
93. Gagnon E, Duclos S, Rondeau C, Chevet E, Cameron PH, et al. 2002. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 110:119-31
94. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, et al. 2003. Phagosomes are competent organelles for antigen cross-presentation. Nature 425:402-6
95. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, van Endert P, Amigorena S. 2003. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425:397-402
96. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:362-68
97. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C. 1997. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27:280-88
98. Yewdell JW, Reits E, Neefjes J. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3:952-61
99. Villanueva MS, Fischer P, Feen K, Pamer EG. 1994. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1:479-89
100. Lelouard H, Gatti E, Cappello F, Gresser O, Camosseto V, Pierre P. 2002. Transient aggregation of ubiquitinated proteins during dendritic cell maturation. Nature 417:177-82
101. Lelouard H, Ferrand V, Marguet D, Bania J, Camosseto V, et al. 2004. Dendritic cell aggresome-like induced structures are dedicated areas for ubiquitination and storage of newly synthesized defective proteins. J. Cell Biol. 164:667-75
102. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. 2003. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 16:324-32
103. Greten TF, Schneck JP. 2002. Development and use of multimeric major histocompatibility complex molecules. Clin. Diagn. Lab. Immunol. 9:216-20
104. Lilley BN, Ploegh HL. 2004. A membrane protein required for dislocation of misfolded proteins from the ER. Nature 429:834-40
105. Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. 2004. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 429:841-47